Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Similar articles for PubMed (Select 19115029)

1.

Basic principles and technologies for deciphering the genetic map of cancer.

Voidonikolas G, Kreml SS, Chen C, Fisher WE, Brunicardi FC, Gibbs RA, Gingras MC.

World J Surg. 2009 Apr;33(4):615-29. doi: 10.1007/s00268-008-9851-y. Review.

2.

Activation of Raf-1 in human pancreatic adenocarcinoma.

Berger DH, Jardines LA, Chang H, Ruggeri B.

J Surg Res. 1997 Apr;69(1):199-204.

PMID:
9202670
3.

Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.

Ottenhof NA, de Wilde RF, Morsink FH, de Leng WW, Ausems MG, Morreau H, van Hillegersberg R, Offerhaus GJ, Milne AN.

Hum Pathol. 2012 Mar;43(3):457-61. doi: 10.1016/j.humpath.2011.06.008. Epub 2011 Oct 10.

4.

Molecular pathobiology of pancreatic adenocarcinoma.

Mangray S, King TC.

Front Biosci. 1998 Nov 15;3:D1148-60. Review.

5.

COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing.

Milbury CA, Correll M, Quackenbush J, Rubio R, Makrigiorgos GM.

Clin Chem. 2012 Mar;58(3):580-9. doi: 10.1373/clinchem.2011.176198. Epub 2011 Dec 21.

6.

Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.

Wang X, Gao J, Ren Y, Gu J, Du Y, Chen J, Jin Z, Zhan X, Li Z, Huang H, Lv S, Gong Y.

Am J Gastroenterol. 2011 Dec;106(12):2104-11. doi: 10.1038/ajg.2011.281. Epub 2011 Aug 30.

PMID:
21876563
7.

Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.

Ruggeri BA, Huang L, Berger D, Chang H, Klein-Szanto AJ, Goodrow T, Wood M, Obara T, Heath CW, Lynch H.

Cancer. 1997 Feb 15;79(4):700-16.

PMID:
9024708
8.

KRAS mutations and their correlation with survival of patients with advanced pancreatic cancer.

Bournet B, Muscari F, Guimbaud R, Cordelier P, Buscail L.

Pancreas. 2013 Apr;42(3):543-4. doi: 10.1097/MPA.0b013e31826b388b. No abstract available.

PMID:
23486365
9.

Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.

Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR.

Cancer Biol Ther. 2008 Mar;7(3):353-360.

10.

Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.

Shin SH, Kim SC, Hong SM, Kim YH, Song KB, Park KM, Lee YJ.

Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0.

PMID:
23344532
11.

Optimizing methods for the diagnosis of pancreatic cancer.

Brugge WR.

J Clin Gastroenterol. 2007 Nov-Dec;41(10):869-70. No abstract available.

PMID:
18090153
12.

Developing a tissue resource to characterize the genome of pancreatic cancer.

Voidonikolas G, Gingras MC, Hodges S, McGuire AL, Chen C, Gibbs RA, Brunicardi FC, Fisher WE.

World J Surg. 2009 Apr;33(4):723-31. doi: 10.1007/s00268-008-9877-1.

13.

Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.

Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Strzelczyk J, Janiak A, Kulig A, Malecka-Panas E.

J Physiol Pharmacol. 2004 Jul;55 Suppl 2:129-38.

14.

Efficient targeted resequencing of human germline and cancer genomes by oligonucleotide-selective sequencing.

Myllykangas S, Buenrostro JD, Natsoulis G, Bell JM, Ji HP.

Nat Biotechnol. 2011 Oct 23;29(11):1024-7. doi: 10.1038/nbt.1996.

15.

Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

Araki T, Shimizu K, Nakamura K, Nakamura T, Mitani Y, Obayashi K, Fujita Y, Kakegawa S, Miyamae Y, Kaira K, Ishidao T, Lezhava A, Hayashizaki Y, Takeyoshi I, Yamamoto K.

J Mol Diagn. 2010 Jan;12(1):118-24. doi: 10.2353/jmoldx.2010.090081. Epub 2009 Dec 10.

16.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049
17.

[Detection of KRAS mutations in tumor cells using biochips].

Emel'ianova MA, Amosenko FA, Chudinov AV, Surzhikov SA, Kazubskaia TP, Liubchenko LN, Nasedkina TV.

Mol Biol (Mosk). 2011 Sep-Oct;45(5):863-70. Russian.

PMID:
22393783
18.

[Kras oncogene and pancreatic cancer: thirty years after].

Bournet B, Dufresne M, Selves J, Torrisani J, Cordelier P, Buscail L.

Med Sci (Paris). 2013 Nov;29(11):991-7. doi: 10.1051/medsci/20132911015. Epub 2013 Nov 20. Review. French.

19.

Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.

van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, Lips EH, Cleton-Jansen AM, Morreau H, van Wezel T.

J Mol Diagn. 2010 Jan;12(1):27-34. doi: 10.2353/jmoldx.2010.090028. Epub 2009 Dec 3.

20.

A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.

Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, Mougin C, Bigand M, Girardo B, Borg C, Ferrand C.

J Mol Diagn. 2011 Sep;13(5):485-92. doi: 10.1016/j.jmoldx.2011.05.010. Epub 2011 Jul 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk